Skip to main content
SpringerLink
Log in

Exogenous Hormones

  • Chapter
  • First Online:
Breast Cancer Epidemiology

Abstract

Women worldwide have been prescribed medications containing female steroid sex hormones for the past several decades. These medications primarily containing various derivatives of estrogen and/or progesterone have been used for two main purposes, as menopausal hormone therapy (HT) and as contraceptives [primarily in the form of oral contraceptives (OCs)]. Given the central role of hormones in the etiology of breast cancer and the widespread use of these preparations, numerous studies have evaluated the relationship between both HT and various hormonal contraceptives and breast cancer risk. These relationships have been and continue to be of considerable interest to epidemiologists, physicians, and the general population. A summary of this large body of work is provided below including assessments of the impact different types of hormones have on different types of breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Althuis MD, Brogan DD, Coates RJ et al (2003) Breast cancers among very young premenopausal women (United States). Cancer Causes Control 14:151–160

    Article  PubMed  Google Scholar 

  • Althuis MD, Brogan DR, Coates RJ et al (2003) Hormonal content and potency of oral contraceptives and breast cancer risk among young women. Br J Cancer 88:50–57

    Article  CAS  PubMed  Google Scholar 

  • Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME (2004) Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 13:1558–1568

    CAS  PubMed  Google Scholar 

  • Benagiano G, Primiero FM, Farris M (2004) Clinical profile of contraceptive progestins. Eur J Contracept Reprod Health Care 9:182–193

    Article  CAS  PubMed  Google Scholar 

  • Benz CC, Clarke CA, Moore DH (2003) Geographic excess of estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev 12:1523–1527

    PubMed  Google Scholar 

  • The WHO Collaborative Study of Neoplasia and Steroid Contraceptives (1990) Breast cancer and combined oral contraceptives: results from a multinational study. Br J Cancer 61:110–119

    Google Scholar 

  • WHO Collaborative Study of Neoplasia and Steroid Contraceptives (1991) Breast cancer and depot-medroxyprogesterone acetate: a multinational study. Lancet 338:833–838

    Article  Google Scholar 

  • Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347:1713–1727

    Article  Google Scholar 

  • Brinton LA, Daling JR, Liff JM et al (1995) Oral contraceptives and breast cancer risk among younger women. J Nat Cancer Inst 87:827–835

    Article  CAS  PubMed  Google Scholar 

  • Britton JA, Gammon MD, Schoenberg JB et al (2002) Risk of breast cancer classified by joint estrogen receptor and progesterone receptor status among women 20–44 years of age. Am J Epidemiol 156:507–516

    Article  PubMed  Google Scholar 

  • Brody SA, Turkes A, Goldzieher JW (1989) Pharmacokinetics of three bioequivalent norethindrone/mestranol-50 micrograms and three norethindrone/ethinyl estradiol-35 micrograms OC formulations: are "low-dose" pills really lower?. Contraception 40:269–284

    Article  CAS  PubMed  Google Scholar 

  • Buist DS, Newton KM, Miglioretti DL et al (2004) Hormone therapy prescribing patterns in the United States. Obstet Gynecol 104:1042–1050

    PubMed  Google Scholar 

  • Burkman RT, Collins JA, Shulman LP, Williams JK (2001) Current perspectives on oral contraceptive use. Am J Obstet Gynecol 185:S4–S12

    Article  CAS  PubMed  Google Scholar 

  • Campagnoli C, Abba C, Ambroggio S, Peris C (2005) Pregnancy, progesterone and progestins in relation to breast cancer risk. J Steroid Biochem Mol Biol 97:441–450

    Article  CAS  PubMed  Google Scholar 

  • Casey PM, Cerhan JR, Pruthi S (2008) Oral contraceptive use and risk of breast cancer. Mayo Clinic Proc 83:86–90

    Article  Google Scholar 

  • Chen CL, Weiss NS, Newcomb P, Barlow W, White E (2002) Hormone replacement therapy in relation to breast cancer. JAMA 287:734–741

    Article  CAS  PubMed  Google Scholar 

  • Chen CL, Weiss NS, Newcomb P, Barlow W, White E (2002) Hormone replacement therapy in relation to breast cancer. JAMA 287:734–741

    Article  CAS  PubMed  Google Scholar 

  • Chen WY, Hankinson SE, Schnitt SJ, Rosner BA, Holmes MD, Colditz GA (2004) Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer 101:1490–1500

    Article  CAS  PubMed  Google Scholar 

  • Chlebowski RT, Hendrix SL, Langer RD et al (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA 289:3243–3253

    Article  CAS  PubMed  Google Scholar 

  • Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ (2006) Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol 24:e

    Article  Google Scholar 

  • Claus EB, Stowe M, Carter D (2003) Oral contraceptives and the risk of ductal breast carcinoma in situ. Breast Cancer Res Treat 81:129–136

    Article  CAS  PubMed  Google Scholar 

  • Colditz GA, Hankinson SE, Hunter DJ et al (1995) The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332:1589–1593

    Article  CAS  PubMed  Google Scholar 

  • Colditz GA, Stampfer MJ, Willett WC, Hennekens CH, Rosner B, Speizer FE (1990) Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. JAMA 264:2648–2653

    Article  CAS  PubMed  Google Scholar 

  • Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047–1059

    Article  Google Scholar 

  • Daling JR, Malone KE, Doody DR et al (2002) Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer 95:2455–2464

    Article  CAS  PubMed  Google Scholar 

  • Daling JR, Malone KE, Doody DR et al (2002) Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer 95:2455–2464

    Article  CAS  PubMed  Google Scholar 

  • David PS, Boatwright EA, Tozer BS et al (2006) Hormonal contraception update. Mayo Clinic Proc 81:949–954

    Article  CAS  Google Scholar 

  • Dickey RP (2007) Managing contraceptive pill patients: thirteenth edition. EMIS Medical Publishers, Dallas

    Google Scholar 

  • Dumeaux V, Alsaker E, Lund E (2003) Breast cancer and specific types of oral contraceptives: a large Norwegian cohort study. Int J Cancer 105:844–850

    Article  CAS  PubMed  Google Scholar 

  • Folger SG, Marchbanks PA, McDonald JA et al (2007) Risk of breast cancer associated with short-term use of oral contraceptives. Cancer Causes Control 18:189–198

    Article  PubMed  Google Scholar 

  • Fournier A, Berrino F, Clavel-Chapelon F (2008) Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 107:103–111

    Article  CAS  PubMed  Google Scholar 

  • Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F (2005) Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 114:448–454

    Article  CAS  PubMed  Google Scholar 

  • Gill JK, Press MF, Patel AV, Bernstein L (2006) Oral contraceptive use and risk of breast carcinoma in situ (United States). Cancer Causes Control 17:1155–1162

    Article  PubMed  Google Scholar 

  • Hankinson SE, Colditz GA, Manson JE et al (1997) A prospective study of oral contraceptive use and risk of breast cancer (Nurses' Health Study, United States). Cancer Causes Control 8:65–72

    Article  CAS  PubMed  Google Scholar 

  • Hatcher RA, Trussell J, Nelson AL, Cates W, Stewart FH, Kowal D (2007) Contraceptive technology: nineteenth revised edition. Ardent Media, Inc., New York

    Google Scholar 

  • Hersh AL, Stefanick ML, Stafford RS (2004) National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291:47–53

    Article  CAS  PubMed  Google Scholar 

  • Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG (2000) Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol 151:703–714

    CAS  PubMed  Google Scholar 

  • Isaksson E, von Schoultz E, Odlind V et al (2001) Effects of oral contraceptives on breast epithelial proliferation. Breast Cancer Res Treat 65:163–169

    Article  CAS  PubMed  Google Scholar 

  • Jeng MH, Parker CJ, Jordan VC (1992) Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation. Cancer Res 52:6539–6546

    CAS  PubMed  Google Scholar 

  • Jick SS, Walker AM, Stergachis A, Jick H (1989) Oral contraceptives and breast cancer. Br J Cancer 59:618–621

    CAS  PubMed  Google Scholar 

  • Kahlenborn C, Modugno F, Potter DM, Severs WB (2006) Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. Mayo Clinic Proc 81:1290–1302

    Article  Google Scholar 

  • Kumle M, Weiderpass E, Braaten T, Persson I, Adami HO, Lund E (2002) Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women’s Lifestyle and Health Cohort Study. Cancer Epidemiol Biomarkers Prev 11:1375–1381

    CAS  PubMed  Google Scholar 

  • Largent JA, Ziogas A (2005) nton-Culver H. Effect of reproductive factors on stage, grade and hormone receptor status in early-onset breast cancer. Breast Cancer Res 7:R541–R554

    Article  CAS  PubMed  Google Scholar 

  • Lee E, Ma H, Kean-Cowdin R et al (2008) Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study. Cancer Epidemiol Biomarkers Prev 17:3170–3178

    Article  CAS  PubMed  Google Scholar 

  • Lee NC, Rosero-Bixby L, Oberle MW, Grimaldo C, Whatley AS, Rovira EZ (1987) A case-control study of breast cancer and hormonal contraception in Costa Rica. J Natl Cancer Inst 79:1247–1254

    CAS  PubMed  Google Scholar 

  • Lee S, Kolonel L, Wilkens L, Wan P, Henderson B, Pike M (2006) Postmenopausal hormone therapy and breast cancer risk: the Multiethnic Cohort. Int J Cancer 118:1285–1291

    Article  CAS  PubMed  Google Scholar 

  • Levi F, Te VC, Randimbison L, La VC (2003) Increase in lobular breast cancer incidence in Switzerland. Int J Cancer 107:164–165

    Article  CAS  PubMed  Google Scholar 

  • Li CI, Anderson BO, Daling JR, Moe RE (2003) Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA 289:1421–1424

    Article  PubMed  Google Scholar 

  • Li CI, Anderson BO, Porter P, Holt SK, Daling JR, Moe RE (2000) Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer 88:2561–2569

    Article  CAS  PubMed  Google Scholar 

  • Li CI, Malone KE, Porter PL et al (2003) Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289:3254–3263

    Article  CAS  PubMed  Google Scholar 

  • Li CI, Malone KE, Porter PL et al (2008) Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas. Cancer Epidemiol Biomarkers Prev 17:43–50

    Article  PubMed  Google Scholar 

  • Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Daling JR (2003) Reproductive and anthropometric factors in relation to the risk of lobular and ductal breast carcinoma among women 65–79 years of age. Int J Cancer 107:647–651

    Article  CAS  PubMed  Google Scholar 

  • Li CI, Weiss NS, Stanford JL, Daling JR (2000) Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer 88:2570–2577

    Article  CAS  PubMed  Google Scholar 

  • Marchbanks PA, McDonald JA, Wilson HG et al (2002) Oral contraceptives and the risk of breast cancer. N Engl J Med 346:2025–2032

    Article  CAS  PubMed  Google Scholar 

  • Miller DR, Rosenberg L, Kaufman DW, Schottenfeld D, Stolley PD, Shapiro S (1986) Breast cancer risk in relation to early oral contraceptive use. Obstetrics Gynecol 68:863–868

    CAS  Google Scholar 

  • Million Women Study Collaborators, Beral V (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419–427

    Article  CAS  PubMed  Google Scholar 

  • Mishell DR Jr (1996) Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med 41:381–390

    CAS  PubMed  Google Scholar 

  • Mosher WD, Martinez G (2004) Use of contraception and use of family planning services in the United States: 1982–2002. Adv Data Vital Health Stat 350:1–46

    Google Scholar 

  • Newcomb PA, Longnecker MP, Storer BE et al (1996) Recent oral contraceptive use and risk of breast cancer (United States). Cancer Causes Control 7:525–532

    Article  CAS  PubMed  Google Scholar 

  • Newcomb PA, Titus-Ernstoff L, Egan KM et al (2002) Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 11:593–600

    CAS  PubMed  Google Scholar 

  • Newcomer LM, Newcomb PA, Potter JD et al (2003) Postmenopausal hormone therapy and risk of breast cancer by histologic type (United States). Cancer Causes Control 14:225–233

    Article  PubMed  Google Scholar 

  • Newcomer LM, Newcomb PA, Trentham-Dietz A, Longnecker MP, Greenberg ER (2003) Oral contraceptive use and risk of breast cancer by histologic type. Int J Cancer 106:961–964

    Article  CAS  PubMed  Google Scholar 

  • Nichols HB, Trentham-Dietz A, Egan KM, Titus-Ernstoff L, Hampton JM, Newcomb PA (2007) Oral contraceptive use and risk of breast carcinoma in situ. Cancer Epidemiol Biomarkers Prev 16:2262–2268

    Article  CAS  PubMed  Google Scholar 

  • Nyante SJ, Gammon MD, Malone KE, Daling JR, Brinton LA (2008) The association between oral contraceptive use and lobular and ductal breast cancer in young women. Int J Cancer 122:936–941

    Article  CAS  PubMed  Google Scholar 

  • Olsson HL, Ingvar C, Bladstrom A (2003) Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 97:1387–1392

    Article  PubMed  Google Scholar 

  • Ortiz A, Hirol M, Stanczyk FZ, Goebelsmann U, Mishell DR (1977) Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA. J Clin Endocrinol Metab 44:32–38

    Article  CAS  PubMed  Google Scholar 

  • Paul C, Skegg DC, Spears GF (1989) Depot medroxyprogesterone (Depo-Provera) and risk of breast cancer. BMJ 299:759–762

    Article  CAS  PubMed  Google Scholar 

  • Pike MC, Henderson BE, Krailo MD, Duke A, Roy S (1983) Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use. Lancet 2:926–930

    Article  CAS  PubMed  Google Scholar 

  • Piper JM, Kennedy DL (1987) Oral contraceptives in the United States: trends in content and potency. Int J Epidemiol 16:215–221

    Article  CAS  PubMed  Google Scholar 

  • Porch JV, Lee IM, Cook NR, Rexrode KM, Burin JE (2002) Estrogen-progestin replacement therapy and breast cancer risk: the Women’s Health Study (United States). Cancer Causes Control 13:847–854

    Article  PubMed  Google Scholar 

  • Reeves GK, Beral V, Green J, Gathani T, Bull D (2006) Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 7:910–918

    Article  CAS  PubMed  Google Scholar 

  • Romieu I, Berlin JA, Colditz GA (1990) Oral contraceptives and breast cancer. Review and meta-analysis. Cancer 66:2253–2263

    Article  CAS  PubMed  Google Scholar 

  • Romieu I, Willett WC, Colditz GA et al (1989) Prospective study of oral contraceptive use and risk of breast cancer in women. J Nat Cancer Inst 81:1313–1321

    Article  CAS  PubMed  Google Scholar 

  • Rookus MA, van Leeuwen FE (1994) Oral contraceptives and risk of breast cancer in women aged 20–54 years. Netherlands Oral Contraceptives and Breast Cancer Study Group. Lancet 344:844–851

    Article  CAS  PubMed  Google Scholar 

  • Rosenberg L, Palmer JR, Rao RS et al (1996) Case-control study of oral contraceptive use and risk of breast cancer. Am J Epidemiol 143:25–37

    CAS  PubMed  Google Scholar 

  • Rosenberg LU, Einarsdottir K, Friman EI et al (2006) Risk factors for hormone receptor-defined breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 15:2482–2488

    Article  CAS  PubMed  Google Scholar 

  • Rosenberg LU, Magnusson C, Lindstrom E, Wedren S, Hall P, Dickman PW (2006) Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study. Breast Cancer Res 8:R11

    Article  PubMed  Google Scholar 

  • Ross RK, Paganini-Hill A, Wan PC, Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92:328–332

    Article  CAS  PubMed  Google Scholar 

  • Rossing MA, Stanford JL, Weiss NS, Habel LA (1996) Oral contraceptive use and risk of breast cancer in middle-aged women. Am J Epidemiol 144:161–164

    CAS  PubMed  Google Scholar 

  • Schindler AE, Campagnoli C, Druckmann R et al (2003) Classification and pharmacology of progestins. Maturitas 46(Suppl 1):S7–S16

    Article  CAS  PubMed  Google Scholar 

  • Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM (2002) Injectable hormone contraception and bone density: results from a prospective study. Epidemiology 13:581–587

    Article  PubMed  Google Scholar 

  • Shapiro S, Rosenberg L, Hoffman M et al (2000) Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives. Am J Epidemiol 151:396–403

    CAS  PubMed  Google Scholar 

  • Stadel BV, Rubin GL, Webster LA, Schlesselman JJ, Wingo PA (1985) Oral contraceptives and breast cancer in young women. Lancet 2:970–973

    Article  CAS  PubMed  Google Scholar 

  • Stahlberg C, Pedersen AT, Andersen ZJ et al (2004) Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy. Br J Cancer 91:644–650

    CAS  PubMed  Google Scholar 

  • Stefanick ML, Anderson GL, Margolis KL et al (2006) Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295:1647–1657

    Article  CAS  PubMed  Google Scholar 

  • Tamimi RM, Hankinson SE, Chen WY, Rosner B, Colditz GA (2006) Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch Int Med 166:1483–1489

    Article  CAS  Google Scholar 

  • The Women’s Health Initiative Steering Committee (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291:1701–1712

    Article  Google Scholar 

  • Ursin G, Ross RK, Sullivan-Halley J, Hanisch R, Henderson B, Bernstein L (1998) Use of oral contraceptives and risk of breast cancer in young women. Breast Cancer Res Treat 50:175–184

    Article  CAS  PubMed  Google Scholar 

  • Ursin G, Tseng CC, Paganini-Hill A et al (2002) Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer? J Clin Oncol 20:699–706

    Article  CAS  PubMed  Google Scholar 

  • Van Hoften C, Burger H, Peeters PH, Grobbee DE, Van Noord PA, Leufkens HG (2000) Long-term oral contraceptive use increases breast cancer risk in women over 55 years of age: the DOM cohort. Int J Cancer 87:591–594

    Article  PubMed  Google Scholar 

  • Verkooijen HM, Fioretta G, Vlastos G et al (2003) Important increase of invasive lobular breast cancer incidence in Geneva, Switzerland. Int J Cancer 104:778–781

    Article  CAS  PubMed  Google Scholar 

  • Wei F, Miglioretti DL, Connelly MT et al (2005) Changes in women’s use of hormones after the Women’s Health Initiative estrogen and progestin trial by race, education, and income. J Natl Cancer Inst Monogr 106–112

    Google Scholar 

  • Weiss LK, Burkman RT, Cushing-Haugen KL et al (2002) Hormone replacement therapy regimens and breast cancer risk. Obstet Gynecol 100:1148–1158

    Article  CAS  PubMed  Google Scholar 

  • White E, Malone KE, Weiss NS, Daling JR (1994) Breast cancer among young U.S. women in relation to oral contraceptive use. J Natl Cancer Inst 86:505–514

    Article  CAS  PubMed  Google Scholar 

  • Wingo PA, Lee NC, Ory HW, Beral V, Peterson HB, Rhodes P (1991) Age-specific differences in the relationship between oral contraceptive use and breast cancer. Obstet Gynecol 78:161–170

    CAS  PubMed  Google Scholar 

  • Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333

    Article  Google Scholar 

  • Wysowski DK, Golden L, Burke L (1995) Use of menopausal estrogens and medroxyprogesterone in the United States, 1982–1992. Obstet Gynecol 85:6–10

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    Christopher I Li & Elisabeth F Beaber

Authors
  1. Christopher I Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elisabeth F Beaber
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher I Li .

Editor information

Editors and Affiliations

  1. Fairview Ave. N., 1100, Seattle, 98109, U.S.A.

    Christopher Li

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Li, C.I., Beaber, E.F. (2010). Exogenous Hormones. In: Li, C. (eds) Breast Cancer Epidemiology. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0685-4_5

Download citation

Publish with us

Policies and ethics

Search

Navigation